Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant

Table 2

Functional outcomes: visual acuity before any intravitreal injection (baseline) and before and after switch to aflibercept at M3 and M6.

	Baseline	Preswitch	M3 postswitch	M6 postswitch
Number of eyes	25	25	25	25
Mean letter score (SD)	52.9 (16.5)	57.1 (19.6)	65.5 (16.4)	65.1 (15.2)
F	2.914
value (ANOVA test)	0.04
Mean VA change from preswitch (SD)			8.4 (14.1)	8 (15.1)
value (compared to preswitch VA)			0.006	0.01
Mean VA change from baseline (SD)		4.2 (3.3)	12.6 (11.6)	12.2
value (compared to preswitch VA)		0.34	<0.0001	0.0003

F: result of variance test (ordinary one-way ANOVA). Except for ANOVA test, values were obtained after a paired parametric t-test after verification of the normal distribution. <0.05; <0.01; <0.001; and <0.0001.